Berkeley Lights, Inc. (BLI) stock prices were down by 3.18% as of the market closing on May 28th, 2021, bringing the price per share down to USD$43.50 at the end of the trading day.
Revenue Reports and Growth in Bases
The leader in Digital Cell Biology reported having generated USD$18.6 million in total revenue over the course of the first quarter of the fiscal year 2021. This represents a 35% increase from the numbers reported for the same quarter of the previous year. The first fiscal quarter of 2021 also saw growth in the company’s installed bases. As of March 31st, 2021, BLI reported 85 platforms. The successful completion of a joint development and partnership program had seen the inclusion of 8 new direct placements.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Launch of Opto Assure
The company also announced the launch of Opto Assure over the course of Q1 2021. Opto Assure is at the forefront of a series of assays that are designed to provide data about yield and product quality at an earlier stage in cell development than offered by existing tools.
Opto Assure Functionality
The first of the series facilitates the direct detection of product aggregates, which, in turn, ensures a speedier ramp towards volume production. This is made by possible by the evaluation of biotherapeutics protein quality sooner in the antibody therapeutic development process. Opto Assure will allow for customers to rapidly select clonal cell lines that have favorable manufacturability profiles. This leads to lower scale-up costs and better downstream products.
Scope of Opto Assure
The emergence of complex antibody therapeutic formats has made cell line development more challenging. The highly engineered proteins have a tendency to suffer from quality issues, including, but not limited to, aggregation, by-products, and post-translational modifications, all of which impact drug manufacturability, shelf life, and safety. BLI has consolidated its technology leadership position in cell line development by going the extra mile beyond titer assessment in the clone selection process. Opto Assure diminishes the risk of expensive late-stage failures by identifying clones earlier on in the process that secrete products with high yield and desired quality.
Future Outlook for BLI
Armed with the revolutionary Opto Assure, the company is pushing for its commercialization and proliferation in the global market to maximize profitability. Current and potential investors are hopeful that the company will continue to leverage the resources at its disposal to usher in significant and sustained increases in shareholder value.
